Myocardial Ischemia-Pipeline Review, H1 2016

Myocardial Ischemia-Pipeline Review, H1 2016


  • Products Id :- GMDHC7730IDB
  • |
  • Pages: 84
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Myocardial Ischemia-Pipeline Review, H1 2016', provides an overview of the Myocardial Ischemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Myocardial Ischemia

The report reviews pipeline therapeutics for Myocardial Ischemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Myocardial Ischemia therapeutics and enlists all their major and minor projects

The report assesses Myocardial Ischemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Myocardial Ischemia

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Myocardial Ischemia Overview 8

Therapeutics Development 9

Pipeline Products for Myocardial Ischemia-Overview 9

Pipeline Products for Myocardial Ischemia-Comparative Analysis 10

Myocardial Ischemia-Therapeutics under Development by Companies 11

Myocardial Ischemia-Therapeutics under Investigation by Universities/Institutes 13

Myocardial Ischemia-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Myocardial Ischemia-Products under Development by Companies 17

Myocardial Ischemia-Products under Investigation by Universities/Institutes 18

Myocardial Ischemia-Companies Involved in Therapeutics Development 19

Baxalta Incorporated 19

Bayer AG 20

Cellmid Limited 21

CohBar, Inc. 22

Lixte Biotechnology Holdings, Inc. 23

NoNO, Inc. 24

Symic Biomedical, Inc. 25

Taxus Cardium Pharmaceuticals Group Inc. 26

ViroMed Co., Ltd. 27

Myocardial Ischemia-Therapeutics Assessment 28

Assessment by Monotherapy Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

AB-002-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Alda-1-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

alferminogene tadenovec-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

AntimiR-199a-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

BAY-606583-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

CMK-103-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

EP-80317-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Humanin-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

LB-100-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Peptagon-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

PMC-6-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

SB-030-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Small Molecules to Inhibit Mst1 for Myocardial Ischemia-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Stem Cell Therapy for Cardiovascular Diseases-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

VM-202-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Myocardial Ischemia-Recent Pipeline Updates 62

Myocardial Ischemia-Dormant Projects 70

Myocardial Ischemia-Discontinued Products 71

Myocardial Ischemia-Product Development Milestones 72

Featured News & Press Releases 72

May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities 72

Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum 73

Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City 75

Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology 76

Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention 77

Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings 77

May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy 78

Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease 80

Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy 82

May 18, 2012: New drug discovery collaborations with Queen Mary University of London launched 82

Appendix 83

Methodology 83

Coverage 83

Secondary Research 83

Primary Research 83

Expert Panel Validation 83

Contact Us 83

Disclaimer 84

List of Figures

Number of Products under Development for Myocardial Ischemia, H1 2016 9

Number of Products under Development for Myocardial Ischemia-Comparative Analysis, H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Comparative Analysis by Early Stage Products, H1 2016 16

Assessment by Monotherapy Products, H1 2016 28

Number of Products by Top 10 Targets, H1 2016 29

Number of Products by Stage and Top 10 Targets, H1 2016 29

Number of Products by Top 10 Mechanism of Actions, H1 2016 31

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 31

Number of Products by Routes of Administration, H1 2016 33

Number of Products by Stage and Routes of Administration, H1 2016 33

Number of Products by Molecule Types, H1 2016 35

Number of Products by Stage and Molecule Types, H1 2016 35

List of Tables

Number of Products under Development for Myocardial Ischemia, H1 2016 9

Number of Products under Development for Myocardial Ischemia-Comparative Analysis, H1 2016 10

Number of Products under Development by Companies, H1 2016 12

Number of Products under Investigation by Universities/Institutes, H1 2016 13

Comparative Analysis by Late Stage Development, H1 2016 14

Comparative Analysis by Clinical Stage Development, H1 2016 15

Comparative Analysis by Early Stage Development, H1 2016 16

Products under Development by Companies, H1 2016 17

Products under Investigation by Universities/Institutes, H1 2016 18

Myocardial Ischemia-Pipeline by Baxalta Incorporated, H1 2016 19

Myocardial Ischemia-Pipeline by Bayer AG, H1 2016 20

Myocardial Ischemia-Pipeline by Cellmid Limited, H1 2016 21

Myocardial Ischemia-Pipeline by CohBar, Inc., H1 2016 22

Myocardial Ischemia-Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016 23

Myocardial Ischemia-Pipeline by NoNO, Inc., H1 2016 24

Myocardial Ischemia-Pipeline by Symic Biomedical, Inc., H1 2016 25

Myocardial Ischemia-Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H1 2016 26

Myocardial Ischemia-Pipeline by ViroMed Co., Ltd., H1 2016 27

Assessment by Monotherapy Products, H1 2016 28

Number of Products by Stage and Target, H1 2016 30

Number of Products by Stage and Mechanism of Action, H1 2016 32

Number of Products by Stage and Route of Administration, H1 2016 34

Number of Products by Stage and Molecule Type, H1 2016 36

Myocardial Ischemia Therapeutics-Recent Pipeline Updates, H1 2016 62

Myocardial Ischemia-Dormant Projects, H1 2016 70

Myocardial Ischemia-Discontinued Products, H1 2016 71

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Baxalta Incorporated Bayer AG Cellmid Limited CohBar, Inc. Lixte Biotechnology Holdings, Inc. NoNO, Inc. Symic Biomedical, Inc. Taxus Cardium Pharmaceuticals Group Inc. ViroMed Co., Ltd.

Myocardial Ischemia Therapeutic Products under Development, Key Players in Myocardial Ischemia Therapeutics, Myocardial Ischemia Pipeline Overview, Myocardial Ischemia Pipeline, Myocardial Ischemia Pipeline Assessment

select a license
Single User License
USD 2000 INR 143800
Site License
USD 4000 INR 287600
Corporate User License
USD 6000 INR 431400

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com